Business Daily from THE HINDU group of publications
Friday, Jun 22, 2007
ePaper


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements
Marketing - New Products & Services
HealthCare Global to launch 2 cancer drugs

Madhumathi D.S.

In contract manufacturing deal with Ahmedabad firm

Bangalore June 21 Cancer hospitals group HealthCare Global Enterprises, flush with two funds for expansion, is all set to launch two cancer drugs contract-manufactured for it by an Ahmedabad-based company.

HCG has tied up with bulk drug producer Sun Moon Industries to make generic formulations of paclitaxol and docetaxol. The products may be out in mid-July, Dr Ajai Kumar, promoter and CEO of Bangalore-based HCG Ltd, told Business Line.

The partnership, initially to supply to HCG's eight cancer hospitals, may be extended to more drugs, and also to domestic and US markets later, depending on its success, he said. The two drugs are used to treat a variety of cancers ranging from oral, head and neck, ovarian and breast cancer.

The aim was to provide HCG patients with cancer drugs that would be 25 per cent lower than the prevailing cost. Some medicine, prescribed for six months, cost Rs 8,000-10,000 a month; radiation and surgery would each amount to Rs 60,000-1 lakh. At least the medication — for the present meant for patients across HCG's eight centres — could be lower as the HCG-Sun Moon arrangement eliminates the trade, according to Dr Kumar.

HCG has invested a small amount in the arrangement. A similar network, US Oncology, according to him, also has such sourcing tie-ups with drug manufacturers.

Fund inflow

HCG has just received a $5-million fund from Evolvence India Life Sciences Fund for part of its Rs 150-crore expansion drive covering 35 centres.

Dr Kumar said acquisition deals were completed or were being finalised in Ahmedabad, Delhi, Kolkata, Ranchi and Nashik, mostly for stakes of 60-65 per cent in local hospitals.

Last July, the cancer care group received Rs 50 crore in funding from IDFC Private Equity. It runs a contract research and clinical trials organisation called Triesta Sciences.

More Stories on : Announcements | New Products & Services | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Sony Ericsson setting up R&D unit in Chennai


HealthCare Global to launch 2 cancer drugs
BEML making stainless steel metro coaches for Mumbai, Kolkata
No intention to withdraw Ikon, says Ford
Varun Shipping buys VLCC
Tantia Const net rises to Rs 13 cr
L&T to build 2 ships for Dutch co BigLift
Mahindra Shaan wins global prize for innovative design in engg
`Efficacy' factor will be key to Glivec patent case
Cabinet allows Mittal to pick up 49% stake in Bhatinda refinery
Danone stake sale talk boosts Britannia stock
PerkinElmer buys 100% in Indian arm
Batliboi buys 70% stake in French co
Finolex Ind in deal with Tishman Speyer for land sale
Land allotment for Jindal plant flayed
Essar Global completes Canada's Algoma buy
NRB Bearings setting up plant in Thailand
IHC in pact with Jalan to set up Gateway hotel
Grindwell ties up with Singye
Tata Motors initiates health camp in Singur
Microsoft ad platform targets social network sites
Fenesta capacity to be doubled
Reliance Money claims `good' client base
Apeejay Surrendra group plans string of hotels
Schwing Stetter sees robust demand for ready mix concrete
GAIL to complete Dahej-Uran-Dabhol pipeline by June 30


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line